Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC
Hepatocellular carcinoma (HCC) is one of the primary types of cancer that claims many lives worldwide, and its incidence continues to increase. Conventional therapies against liver cancer are inadequate, and the pathogenesis of HCC remains unclear. Thus, not only are more effective therapies to trea...
Saved in:
Main Authors: | Yulong Wei, Qingzhu Song, Fenglan Zhang, Tian Yuan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2021/5601678 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC
by: Gulizaina Hapaer, et al.
Published: (2025-01-01) -
Exploring prognosis and therapeutic strategies for HBV-HCC patients based on disulfidptosis-related genes
by: Chuankuo Zhang, et al.
Published: (2025-01-01) -
HCC Heterogeneity: Molecular Pathogenesis and Clinical Implications
by: Emilia Fransvea, et al.
Published: (2009-01-01) -
HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation
by: Juliet A. Emamaullee, et al.
Published: (2019-01-01) -
HBV DNA integration and somatic mutations in HCC patients with HBV-HCV dual infection reveals profiles intermediate between HBV- and HCV-related HCC
by: Chiao-Ling Li, et al.
Published: (2025-01-01)